ClinicalTrials.Veeva
Menu

Find clinical trials for Melanoma in St Louis, MO

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Non-Small-Cell Lung Carcinoma
Renal Cell Carcinoma
Lung Cancer
Squamous Cell Carcinoma

Melanoma trials near St Louis, MO, USA:

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

and overall survival (OS) for patients with NRAS-mutant (NRASm) melanoma who are randomized to receive the combination of naporafenib + tram...

Enrolling
Advanced or Metastatic NRAS-mutant Melanoma
Drug: Trametinib
Drug: Naporafenib

Phase 3

Erasca

Saint Louis, Missouri, United States and 3 other locations

emitting therapeutic agent targeted to melanocortin sub-type 1 receptor (MC1R) is being evaluated in patients with unresectable and metastatic melanoma...

Enrolling
Mucosal Melanoma
Melanoma Stage IV
Drug: [203Pb]VMT01
Drug: [212Pb]VMT01

Phase 1, Phase 2

Perspective Therapeutics

Saint Louis, Missouri, United States and 8 other locations

To evaluate the overall survival of HLA-A\*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investig...

Active, not recruiting
Uveal Melanoma
Biological: IMCgp100
Biological: Pembrolizumab

Phase 2

Immunocore
Immunocore

Saint Louis, Missouri, United States and 55 other locations

antigen (HLA)-A\*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotin...

Enrolling
Metastatic Uveal Melanoma
Drug: IDE196
Drug: Nivolumab

Phase 2, Phase 3

Ideaya Biosciences

Saint Louis, Missouri, United States and 64 other locations

treatment of adult subjects with completely treated high-risk ocular melanoma, as defined in eligibility criteria, without evidence of metas...

Active, not recruiting
Melanoma
Ocular Melanoma
Drug: Ipilimumab
Drug: Nivolumab

Phase 2

Suthee Rapisuwon

Saint Louis, Missouri, United States and 5 other locations

Part 1 is the dose escalation of APG-115 in combination with label dose of pembrolizumab.Part 2 is phase II design of APG-115 at recommended phase 2...

Enrolling
Mucosal Melanoma
Melanoma
Drug: APG-115+Pembrolizumab

Phase 1, Phase 2

Ascentage Pharma Group
Ascentage Pharma Group

Saint Louis, Missouri, United States and 19 other locations

and pembrolizumab improves recurrence free survival (RFS) compared to pembrolizumab alone in participants with complete resection of cutaneous melanoma...

Enrolling
Melanoma
Drug: mRNA-4157
Biological: Pembrolizumab

Phase 2

Moderna
Moderna

Saint Louis, Missouri, United States and 20 other locations

combined with nivolumab on patients with unresectable or metastatic melanoma and eligible patients who are not adolescents or patients with ...

Enrolling
Unresectable or Metastatic Melanoma
Progressive Brain Metastasis
Drug: Placebo in combination with nivolumab
Drug: HBI-8000 in combination with nivolumab

Phase 3

HUYABIO

Bridgeton, Missouri, United States and 141 other locations

The purpose of this study is to determine whether nivolumab is better than ipilimumab to prevent recurrence of melanoma....

Active, not recruiting
Melanoma
Drug: Nivolumab
Other: Placebo matching Nivolumab

Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Saint Louis, Missouri, United States and 135 other locations

(PROs) of autogene cevumeran (RO7198457) plus pembrolizumab compared with pembrolizumab alone in patients with previously untreated advanced melanoma...

Active, not recruiting
Advanced Melanoma
Drug: Pembrolizumab
Biological: Autogene cevumeran

Phase 2

Genentech
Genentech

Saint Louis, Missouri, United States and 56 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems